Polymorphism G80A in the reduced folate carrier gene and its relationship to methotrexate plasma levels and outcome of childhood acute lymphoblastic leukemia. - Wikidata - wikimedia - TriplyDB

Polymorphism G80A in the reduced folate carrier gene and its relationship to methotrexate plasma levels and outcome of childhood acute lymphoblastic leukemia.

Polymorphism G80A in the reduced folate carrier gene and its relationship to methotrexate plasma levels and outcome of childhood acute lymphoblastic leukemia.

http://www.wikidata.org/entity/Q44201573

about

The reduced folate carrier (SLC19A1) c.80G>A polymorphism is associated with red cell folate concentrations among women Pharmacogenomics in Pediatric Oncology: Review of Gene-Drug Associations for Clinical Use Pharmacogenetics predictive of response and toxicity in acute lymphoblastic leukemia therapy Reduced folate carrier and methylenetetrahydrofolate reductase gene polymorphisms: associations with clinical outcome in childhood acute lymphoblastic leukemia Polymorphisms of the vincristine pathway and response to treatment in children with childhood acute lymphoblastic leukemia Polymorphisms of selected xenobiotic genes contribute to the development of papillary thyroid cancer susceptibility in Middle Eastern population Association of genetic polymorphism in the folate metabolic pathway with methotrexate pharmacokinetics and toxicity in childhood acute lymphoblastic leukaemia and malignant lymphoma.Effects of methylenetetrahydrofolate reductase gene polymorphisms on toxicities during consolidation therapy in pediatric acute lymphoblastic leukemia in a Chinese population.Polymorphisms in methotrexate transporters and their relationship to plasma methotrexate levels, toxicity of high-dose methotrexate, and outcome of pediatric acute lymphoblastic leukemia.The association of reduced folate carrier 80G>A polymorphism to outcome in childhood acute lymphoblastic leukemia interacts with chromosome 21 copy number Urinary coproporphyrin I/(I + III) ratio as a surrogate for MRP2 or other transporter activities involved in methotrexate clearance.SLC19A1 pharmacogenomics summary.Geographical and ethnic distribution of single nucleotide polymorphisms within genes of the folate/homocysteine pathway metabolism Old drugs, old problems: where do we stand in prediction of rheumatoid arthritis responsiveness to methotrexate and other synthetic DMARDs?Influence of polymorphisms within the methotrexate pathway genes on the toxicity and efficacy of methotrexate in patients with juvenile idiopathic arthritis.Membrane transporters and folate homeostasis: intestinal absorption and transport into systemic compartments and tissues.PharmGKB summary: methotrexate pathway.RFC1 80G>A is a genetic determinant of methotrexate efficacy in rheumatoid arthritis: a human genome epidemiologic review and meta-analysis of observational studies.What is next in pharmacogenomics? Translating it to clinical practice.Pharmacogenetic determinants of outcome in acute lymphoblastic leukaemia.Ancestry and pharmacogenetics of antileukemic drug toxicity Pharmacogenetics of methotrexate.Contribution of tumoral and host solute carriers to clinical drug response.The RFC1 80G>A, among Common One-Carbon Polymorphisms, Relates to Survival Rate According to DNA Global Methylation in Primary Liver Cancers.Sarcomas and pharmacogenetics.CCND1 G870A polymorphism is associated with toxicity of methotrexate in childhood acute lymphoblastic leukemia Pharmacogenetics of folate-related drug targets in cancer treatment.Folate during antifolate chemotherapy: what we know... and do not know.Acute lymphoblastic leukaemia: a model for the pharmacogenomics of cancer therapy.Review article: interactions between genotype and response to therapy in inflammatory bowel diseases.Influence of genetic polymorphisms in the folate pathway on toxicity after high-dose methotrexate treatment in pediatric osteosarcoma Pharmacogenetics of acute lymphoblastic leukemia treatment response.The genetic architecture of methotrexate toxicity is similar in Drosophila melanogaster and humans.Association of germline genetic variants in RFC, IL15 and VDR genes with minimal residual disease in pediatric B-cell precursor ALL.An update on methotrexate pharmacogenetics in rheumatoid arthritis.Pharmacogenetics of Crohn's disease.Gene polymorphisms in folate metabolizing enzymes in adult acute lymphoblastic leukemia: effects on methotrexate-related toxicity and survival.Germline genetic variation in an organic anion transporter polypeptide associated with methotrexate pharmacokinetics and clinical effects.Genetic and epigenomic footprints of folate.Pharmacogenomics in the treatment of inflammatory bowel disease.

P2860

Q24657376-39661CD9-40AF-4431-9E87-7571CAC8E0B2 Q28068930-0A74F929-5981-468B-AFE6-D4D7E7097DD1 Q28083449-D583910B-293A-4992-BEC2-75E06895A803 Q28240130-88FBECC2-0289-4457-A821-C508156AB19F Q28245060-9ED0BC4D-30A9-4634-9591-545D52203C17 Q33349220-CF65A462-D50A-4221-9331-4537180EC1D8 Q33395001-69E841AE-6ED1-4554-A66E-DA48F0DA6F9C Q33395136-1B414C59-E9BA-4002-877B-3929401D8D69 Q33914131-451688F0-366D-4041-B3C5-3C9D6BE09313 Q33931844-23665495-DE8B-47F6-AD74-69A0688B6ABF Q34065294-2747D8AE-CDF8-4AC7-A5D0-6568B8B22CA1 Q34205753-3CCE9185-06FA-4C18-8FFC-DD94D35D00E9 Q34232715-D309EE8C-261A-4DC7-814A-F0428DE05C12 Q34559803-56F82056-78A9-4BB7-8E79-1A84BFD6EC53 Q34580608-F3569866-DB69-4FF0-8893-74D2E42ED298 Q34658009-422C7498-A02A-4A6D-9A26-07B161F788A9 Q35115680-D57BE518-5322-48C2-8622-CB5B2EDDAB7F Q35159896-3D986FBE-FE88-402E-A5BE-6353DD289269 Q35164680-C1F176D9-1A84-4FF5-91CF-9E31509D16D9 Q35772582-9C599AAC-46D7-4894-801D-6300A7F962D1 Q35828717-CAA342C3-3E86-4BFF-8CCF-58F3B1DE276D Q35911142-33ED25A5-3FA5-4CA4-9122-871603C46595 Q35946876-CB0B1FB0-3460-4324-B00F-7C84568F6BD3 Q36217905-977E1D0A-36D0-4928-BD02-DFAFBF943E39 Q36249224-6DD3442D-E093-4D2E-881D-2986F36740CC Q36261959-03907191-DD9F-43E2-B711-A68E6F777F63 Q36278007-12318C7A-572D-48C8-A8CC-952734C5B537 Q36278412-62D786FB-9013-4AD9-8E01-7BFEE84FBE5F Q36402208-DE99711B-06A4-4C0E-9411-E8E6E45C8AE6 Q36642796-EB7B92BB-45DB-4421-8C51-BAA16FEC5F96 Q36789432-CB94D45E-7DDC-455E-B398-0B1E5C9DE3F7 Q36968156-F9A6B3C2-6646-4340-B343-796187C2A4BC Q37079514-C2F606C6-D1D1-4430-8259-E96C3114B22C Q37101299-9D31543F-2934-4280-99C6-0616F11504F5 Q37126658-3549E275-7D81-4F3A-9BD3-7246061F6631 Q37205946-41D72764-49AA-4E2C-835C-BCF8452E9917 Q37369929-E68B5196-5F9D-49B9-A6ED-F3AC92322917 Q37474395-A2399DCF-8CE2-4E71-BFE5-25B70D951D01 Q37689132-6321C6AE-553A-4000-8861-8D590C573E20 Q37710516-1E684BEA-9BC2-4AA1-A8D0-A4F6DF7F904F

P2860

Polymorphism G80A in the reduced folate carrier gene and its relationship to methotrexate plasma levels and outcome of childhood acute lymphoblastic leukemia.

http://www.wikidata.org/entity/Q44201573

description

2002 nî lūn-bûn

@nan

2002年の論文

@ja

2002年学术文章

@wuu

2002年学术文章

@zh

2002年学术文章

@zh-cn

2002年学术文章

@zh-hans

2002年学术文章

@zh-my

2002年学术文章

@zh-sg

2002年學術文章

@yue

2002年學術文章

@zh-hant

name

Polymorphism G80A in the reduc ...... acute lymphoblastic leukemia.

@en

Polymorphism G80A in the reduc ...... acute lymphoblastic leukemia.

@nl

type

label

Polymorphism G80A in the reduc ...... acute lymphoblastic leukemia.

@en

Polymorphism G80A in the reduc ...... acute lymphoblastic leukemia.

@nl

prefLabel

Polymorphism G80A in the reduc ...... acute lymphoblastic leukemia.

@en

Polymorphism G80A in the reduc ...... acute lymphoblastic leukemia.

@nl

P1433

Q44201573-E5BF51E2-EC14-4D22-A933-591AAE617FAD

P1476

Q44201573-5AC3F460-24CE-4D03-A4B4-933C26A99134

P2093

Q44201573-56858272-383F-4F8E-BB85-092F848FD0E8

Q44201573-572EE99F-2C86-41B6-8EF1-6602C066EE72

Q44201573-70F87F4D-E855-45DD-9FA2-F9C47F90EA34

Q44201573-B9E40F4E-E8B0-4FBA-A0D6-D0C0099E26C7

Q44201573-BB34438D-FDEA-4AD3-826C-E94354C4C683

P304

Q44201573-F88DD82D-E87D-46CE-8119-D3AA5E8C2387

P31

Q44201573-193ABF7B-4C5C-4A01-B0C9-4A63DEE854A2

P356

Q44201573-18A957C3-EB62-4EF2-B94D-5587CD631412

P407

Q44201573-ADDD20C4-FDCE-43F6-AD4F-A4A6276F2A53

P433

Q44201573-59330870-0263-4211-B68B-41762B245438

P478

Q44201573-75178F55-CD04-41C1-89B1-94FD12654199

P577

Q44201573-FDEF0BD8-2833-4607-91A0-2A4F2B0FB803

P698

Q44201573-C91E287F-504E-4543-9054-12F037A6D461

P921

Q44201573-932C911E-B668-403E-A5A5-301633CB0550

P356

BLOOD.V100.10.3832

P1433

P1476

Polymorphism G80A in the reduc ...... acute lymphoblastic leukemia.

@en

P2093

Albert Moghrabi

http://www.w3.org/2001/XMLSchema#string

Caroline Laverdière

http://www.w3.org/2001/XMLSchema#string

Irina Costea

http://www.w3.org/2001/XMLSchema#string

Maja Krajinovic

http://www.w3.org/2001/XMLSchema#string

Sonia Chiasson

http://www.w3.org/2001/XMLSchema#string

P304

3832-3834

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1182/BLOOD.V100.10.3832

http://www.w3.org/2001/XMLSchema#string

P407

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

100

http://www.w3.org/2001/XMLSchema#string

P577

2002-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

12411325

http://www.w3.org/2001/XMLSchema#string

P921